Saturday, June 9

SIMULTANEOUS SESSIONS II

10:30 - 11:45 hours, Room: Mozart I

ACUTE MYELOID LEUKEMIA - CLINICAL

Chairs: B. Löwenberg (Erasmus Medical Center, Rotterdam, The Netherlands) J. Sierra (Hospital de la Santa Creu i Sant Pau, Barcelona, Spain) 10:30 - 10:45

0396 PROGNOSTIC IMPACT OF NPM1 MUTATIONS IN CYTOGENETICALLY NORMAL (CN) ACUTE MYELOID LEUKEMIA (AML) IS ADVERSELY AFFECTED BY HIGH EXPRESSION OF THE ERG GENE: A CANCER AND LEUKEMIA GROUP B (CALGB) STUDY

P. Paschka, G. Marcucci, K. Maharry, S.P. Whitman, A.S. Ruppert, T. Vukosavljevic, K. Mrózek, B.L. Powell, J.E. Kolitz, R.A. Larson, C.D. Bloomfield (The Ohio State University, Columbus, USA) 10:45 - 11:00

0397 PRONOSTIC VALUE OF MOLECULAR FINDINGS IN AML: RESULTS OF THE FRENCH ALFA-9802 TRIAL

V. Biggio, A. Renneville, J.M. Cayuela, S. Hayette, D. Bories, X. Troussard, A.L. Beanceur, N. Fresnoy, N. Philippe, N. Boissel, C. Terre, M. Elhamri, S. Castaigne, H. Dombret, X. Thomas, C. Preudhomme (INSERM, Lille, France) 11:00 - 11:15

0398 THE IMPACT OF THERAPY-RELATED AND SECONDARY AML IN RELATION TO KARYOTYPE AND MOLECULAR MARKERS: A STUDY OF THE AMLSG

S. Kayser, K. Döhner, J. Krauter, S. Groner, D. Späth, B. Schlegelberger, G. Göhring, A. Ganser, H. Döhner, R.F. Schlenk (Uniklinik Ulm, Ulm, Germany) 11:15 - 11:30

0399 INCIDENCE OF RETINOIC ACID SYNDROME DURING INDUCTION THERAPY FOR ACUTE PROMYELOCYTIC LEUKEMIA (PETHEMA PROTOCOLS LPA 96 &9 99) REVEALS TWO PEAKS WITH DIFFERENT INDUCTION MORTALITY

J.M. Bergua, P. Montesinos, G. Guillermo, J. De La Serna, E. Vallenga, C. Rayón, R. Parody, J. Esteve, M. Gonzalez, J. Gonzalez, S. Brunet, M.A. Sanz (Hospial San Pedro Alcántara, Cáceres, Spain) 11:30 - 11:45

0400 PCR-BASED MRD DETECTION IN NPM1 MUTATED AML: A PROSPECTIVE FOLLOW-UP STUDY IN 97 PATIENTS

S. Schnittger, W. Kern, C. Haferlach, T. Haferlach (MLL, Munich, Germany)

SIMULTANEOUS SESSIONS

10:30 - 11:45 hours, Room: Mozart II

MYELOMA / MGUS / WM - CLINICAL

Chairs: J. Bladé (Hospital Clinic, Barcelona, Spain) M. Boccadoro (Università di Torino, Turin, Italy) 10:30 - 10:45

0401 ORAL MELPHALAN, PREDNISONE, THALIDOMIDE VERSUS ORAL MELPHALAN, PREDNISONE IN ELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS

A. Palumbo, S. Bringhen, T. Caravita, A. Falcone, V. Callea, C. Cangialosi, M. Grasso, M. Galli, F. Rossini, L. Catalano, M. Montanaro, V. De Stefano, V. Magarotto, I. Avonto, P. Musto, A.M. Liberati, M. Cavo, M. Boccadoro (Az. Osp. S. Giovanni Battista, Turin, Italy) 10:45 - 11:00

0402 ORAL MELPHALAN, PREDNISONE AND LENALIDOMIDE FOR ELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS

A. Palumbo, P. Falco, P. Corradini, C. Crippa, F. Di Raimondo, A. Falcone, N. Nicola, L. Canepa, A. Gozzetti, F. Morabito, R. Knight, J.B. Zeldis, M. Boccadoro, M.T. Petrucci (Az. Osp. S. Giovanni Battista, Turin, Italy) 11:00 - 11:15

0403 TANDEM AUTOGRAFTING-NONMYELOABLATIVE ALLOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: THE GITMO (GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO) EXPERIENCE

L. Giaccone, F. Patriarca, M. Rotta, N. Mordini, D.G. Maloney, M. Casini, A. Rambaldi, F. Carnevale-Schianca, B. Allione, D. Soligo, P. Bavaro, A.P. Iori, R. Sorasio, F. Fiore, V. Montefusco, A. Busca, A. Parma, L. Castagna, E. Benedetti, R. Fanin, A. Gallamini, P. Corradini, A. Levis, M. Aglietta, E. Pogliani, M. Falda, M. Massaia, A. Palumbo, B. Sandmaier, R. Storb, M. Boccadoro, B. Bruno (Azienda Ospedaliera San Giovanni Battist, Turin, Italy) 11:15 - 11:30

0404 BORTEZOMIB PLUS MELPHALAN AND PREDNISONE (VMP) IN ELDERLY UNTREATED PATIENTS WITH MULTIPLE MYELOMA (MM): PROGNOSTIC FACTORS INFLUENCING TIME TO PROGRESSION

M.-V.M. Mateos, J.-M. Hernández, M.-T. Hernández, N.-C. Gutiérrez, L. Palomera, M. Fuertes, P. García, J.J. Lahuerta, J. De la Rubia, M.J. Terol, A. Sureda, J. Bargay, P. Ribas, F. De Arriba, A. Alegre, A. Oriol, D. Carrera, J. García-Laraña, R. García-Sanz, J. Bladé, F. Prosper, D.-L. Esseltine, H. Van de Velde, J.-F. San-Miguel (University Hospital of Salamanca, Salamanca, Spain) 11:30 - 11:45

0405 POOR PROGNOSIS ASSOCIATED WITH GAIN OF CHROMOSOME 1Q21 IN MULTIPLE MYELOMA MAY BE OVERCOME BY TREATMENT WITH A BORTEZOMIB COMBINATION

V. Sagaster, V. Odelga, H. Kaufmann, J. Ackermann, M. Galhuber, N. Zojer, H. Ludwig, R. Wieser, C. Zielinski, J. Drach (Medical University of Vienna, Vienna, Austria)

SIMULTANEOUS SESSIONS

10:30 - 11:45 hours, Room: Mozart III

NON-HODGKIN'S LYMPHOMA - CLINICAL I

Chairs: M. Björkholm (Karolinska Institute, Stockholm, Sweden) M. Pfreundschuh (Medical University Klinik und Poliklinik, Homburg, Germany) 10:30 - 10:45

0406 PROSPECTIVE, MULTICENTER RANDOMIZED GITMO/IIL TRIAL COMPARING INTENSIVE (R-HDS) VERSUS CONVENTIONAL CHEMOIMMUNOTHERAPY (CHOP-R) IN HIGH-RISK FOLLICULAR LYMPHOMA AT DIAGNOSIS: THE SUPERIOR MOLECULAR REMISSION (MR) RATE OF R-HDS EXPLAINS ITS BETTER CLINICAL PERFORMANCE

M. Ladetto, F. De Marco, F. Benedetti, U. Vitolo, C. Patti, A. Rambaldi, A. Pulsoni, M. Musso, A.M. Liberati, A. Olivieri, A. Gallamini, E. Pogliani, D. Rota Scalabrini, V. Callea, F. Di Raimondo, V. Pavone, A. Tucci, S. Cortelazzo, A. Levis, M. Boccadoro, I. Majolino, A. Pileri, A.M. Gianni, R. Passera, P. Corradini, C. Tarella (Università di Torino, Turin, Italy) 10:45 - 11:00

0407 LONG-TERM RESULTS OF THE GELA STUDY COMPARING R-CHOP AND CHOP CHEMOTHERAPY IN OLDER PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA SHOW A LONG TERM BENEFIT FOR THE ADJUNCTION OF RITUXIMAB TO CHOP

B. Coiffier, P. Feugier, R. Bouabdallah, P. Morel, G. Marit, J. Gabarre, E. Jourdan, A. Delmer, G. Lepeu, H. Tilly (Hospices Civils de Lyon, Pierre-Benite, France) 11:00 - 11:15

0408 ADDITION OF RITUXIMAB TO DOSE-DENSE AND HIGH DOSE CHEMOTHERAPY (HDC) WITH AUTOLOGOUS TRANSPLANTATION (ASCT) IN UNTREATED POOR-PROGNOSIS DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RESULTS OF PHASE II TRIAL

U. Vitolo, M.G. Cabras, G. Rossi, A.M. Liberati, A. Chiappella, A. Levis, V. Pavone, E. Angelucci, B. Botto, G. Ciccone, R. Freilone, G. Gaidano, D. Novero, L. Orsucci, I. Palumbo, E.M. Pogliani, D. Rota Scalabrini, F. Salvi, A. Tonso, A. Tucci, E. Gallo (On the behalf of GIMURELL, Turin, Italy) 11:15 - 11:30

0409 FRACTIONATED RADIOIMMUNOTHERAPY IN NHL WITH DOTA-CONJUGATED, HUMANIZED ANTI-CD22 EPRATUZUMAB AT HIGH CUMULATIVE 90Y DOSES

F. Morschhauser, F. Kraeber-Bodere, M.-O. Petillon, J.-F. Chatal, J.-L. Harousseau, H. Horne, N. Teoh, W.A. Wegener, D.M. Goldenberg (Centre Hospitalier Universitaire, Lille, France) 11:30 - 11:45

0410 HIGH CURE RATE OF ADULT BURKITT'S AND OTHER HIGH GRADE NHL BY THE COMBINATION OF SHORT INTENSIVE CHEMOTHERAPY CYCLES WITH RITUXIMAB D. Hoelzer, W. Hiddemann, A. Baumann

, H. Döhner, U. Dührsen, R. Fietkau, M.-L. Hansmann, A. Hüttmann, S. Irmer, S. Kaun, M. Kneba, A. Reichle, M. Schmid, I. Schmidt-Wolf, E. Thiel, J. Walewski, N. Gökbuget (J.W.Goethe University, Frankfurt Am Main, Germany)

SIMULTANEOUS SESSIONS

10:30 - 11:45 hours, Room: Strauss II

MYELOPROLIFERATIVE DISORDERS - BIOLOGY

Chairs: N. Casadevall (Hospital Hôtel Dieu, Paris, France) N. Cross (University of Southampton, Southampton, United Kingdom) 10:30 - 10:45

0411 ACQUIRED ISODISOMY IS COMMON IN ATYPICAL MYELOPROLIFERATIVE DISORDERS

C. Curtis, F.H. Grand, S. Kreil, D.G. Oscier, A.G Hall, N.C.P Cross (Wessex Regional Genetics Lab, Salisbury, United Kingdom) 10:45 - 11:00

0412 JAK2V617F-NEGATIVE ET PATIENTS DO NOT DISPLAY CONSTITUTIVELY ACTIVE JAK/STAT SIGNALLING

H. Pahl, S. H. Schwemmers, B. Will, C. F. Waller, K. Abdulkarim, P. L. Johansson, B. Andreasson, H. L. Pahl (University Hospital Freiburg, Freiburg, Germany) 11:00 - 11:15

0413 MPL MUTATIONS IN PRIMITIVE MYELOFIBROSIS ARE NOT RESTRICTED TO MPL 515 MUTATIONS BUT ONLY MPL 515 MUTATIONS ARE ONCOGENIC EVENTS PRESENT AT THE STEM CELL LEVEL

S. Giraudier, R. Chaligné, C. James, C. Tonetti, J.P. Le Couédic, R. Besancenot, I. Godin, L. Lordier, K. Malloum, P. Mossuz, M.C. Le Bousse-Kerdilès, W. Vainchenker, S. Giraudier (INSERM, U790 and Hematology Laboratory H, Villejuif And Créteil, France) 11:15 - 11:30

0414 COMPARATIVE ANALYSIS OF THE CONSTITUTIVE ACTIVE JAK2V617F, JAK2T875N AND MPLW515L ALLELES IN A MURINE BONE MARROW TRANSPLANT MODEL OF MYELOPROLIFERATIVE DISEASE

G. Wernig, T. Mercher, Y. Pikman, R.L. Levine, D.G. Gilliland (HMS, Brigham & Women's Hospital, Boston, USA) 11:30 - 11:45

0415 EXPRESSION AND EFFECTS OF NUCLEAR FACTOR-ERYTHROID DERIVED 2 (NF-E2) IN MURINE AND HUMAN HEMATOPOIESIS

B. Will, M. Mutschler, C. Scholl, U. Steidl, E. Levantini, C.S. Huettner, D.G. Tenen, H.L. Pahl (Harvard Medical School, Boston, USA

SIMULTANEOUS SESSIONS

10:30 - 11:45 hours, Room: Strauss III

GENE THERAPY AND IMMUNOTHERAPY

Chairs: M. Sadelain (Memorial Sloan-Kettering Cancer Center, New York, USA) M. van Oers (Academic Medical Center, Amsterdam, The Netherlands) 10:30 - 10:45

0416 DUAL SYSTEM OF RNA TRANS-SPLICING ELEMENT AND SLEEPING BEAUTY TRANSPOSON CORRECTS DNA PROTEIN KINASE MUTATION IN SEVERE COMBINED IMMUNE DEFICIENCY

J. Tolar, H. Zayed, L. Xia, A. Yerich, S.R. Yant, M.A. Kay, M. Puttaraju, S.G. Mansfield, D. Wiest, R.S. McIvor, B.R. Blazar (University of Minnesota, Minneapolis, USA) 10:45 - 11:00

0417 RHAMM/CD168-R3 PEPTIDE VACCINATION OF PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML), MYELODYSPLASTIC SYNDROME (MDS), MULTIPLE MYELOMA (MM) AND CHRONIC LYMPHATIC LEUKEMIA (CLL) ELICITS IMMUNOLOGICAL AND CLINICAL RESPONSES

J. Greiner, A. Schmitt, K. Giannopoulos, J. Chen, P. Liebisch, M. Ringhoffer, P. Guillaume, G. Ritter, M. Bommer, M. Rojewski, S. Gnjatic, H. Döhner, M. Schmitt (University of Ulm, Ulm, Germany) 11:00 - 11:15

0418 FEASIBILITY STUDY OF RITUXIMAB FOLLOWED BY ANTI-IDIOTYPE IMMUNOTHERAPY WITH TUMOR-SPECIFIC IDIOTYPE-KLH (FAVID®) AND GM-CSF IN INDOLENT B-CELL LYMPHOMAS

E. Zucca, F. Cavalli, F. Bertoni, D. Rodriguez-Abreu, V. Belisario Filho, E. Ceresa, B. Dossena, L. Ponsanesi, R.M. Diaz Borrell, T. Terrot, V. Esquibel, J. Gutheil, D. Johnson (Oncology Inst. of Southern Swtizerland, Bellinzona, Switzerland) 11:15 - 11:30

0419 ACUTE MYELOID LEUKEMIA (AML)-REACTIVE CYTOTOXIC T LYMPHOCYTE CLONES RAPIDLY EXPANDED FROM CD8+ CD62L(HIGH)+ T CELLS OF HEALTHY DONORS PREVENT AML ENGRAFTMENT IN NOD/SCID IL2R GAMMA NULL MICE

E. Distler, C. Woelfel, S. Koehler, M. Nonn, N. Kaus, E. Schnuerer, R.G. Meyer, T.C. Wehler, C. Huber, T. Woelfel, U.F. Hartwig, W. Herr (Johannes Gutenberg-University Mainz, Mainz, Germany) 11:30 - 11:45

0420 A COMPARATIVE ANALYSIS OF THE LEUKAEMIC POTENTIAL OF MATURE T CELLS VERSUS HEMATOPOIETIC STEM CELLS

S.N. Newrzela, Z. Li, C. Baum, M. Hartmann, S. Hartmann, M.-L. Hansmann, K. Cornils, B. Fehse, M.D. Von Laer (Georg-Speyer-Haus, Frankfurt Am Main, Germany)

SIMULTANEOUS SESSIONS

10:30 - 11:45 hours, Room: Léhar I+II

STEM CELL TRANSPLANTATION II

Chairs: F. Frassoni (Ospedale San Martino, Genoa, Italy) F. Dazzi (Imperial College, London, United Kingdom) 10:30 - 10:45

0421 GRAFT-VERSUS-LEUKEMIA INDUCED BY GRAFT-VERSUS-HOST DISEASE EARLY AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION IN CHILDREN WITH DETECTABLE LEVELS OF RESIDUAL ACUTE LYMPHOBLASTIC LEUKEMIA PRIOR TO TRANSPLANTATION

M. Bierings, A. Lankester, V.J.V. van der Velden, E. van Wering, T. Revesz, A. Wijkhuis, J.J.M. van Dongen, M. Van Tol, M. Egeler, M.W. Schilham (Wilhelmina Children's Hospital, Utrecht, The Netherlands) 10:45 - 11:00

0422 A PROSPECTIVE RANDOMIZED TRIAL OF TWO DOSE-INTENSIVE MELPHALAN REGIMENS (100 VS 200MG/MQ) IN NEWLY DIAGNOSED MYELOMA PATIENTS

A. Palumbo, S. Bringhen, M.T. Petrucci, A. Falcone, A.M. Liberati, M. Grasso, F. Pisani, C. Cangialosi, T. Caravita, F. D'Agostino, F. Cavallo, P. Omedè, P. Musto, R. Foà, M. Boccadoro (Az. Osp. S. Giovanni Battista, Turin, Italy) 11:00 - 11:15

0423 A RAPID CLEARANCE OF MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION PREDICTS THE CLINICAL OUTCOME OF HIGH RISK ADULT ALL PATIENTS

O. Spinelli, B. Peruta, M. Tosi, V. Guerini, A. Salvi, M.C. Zanotti, E. Oldani, A. Grassi, T. Intermesoli, C. Micò, G. Rossi, P. Fabris, G. Lambertenghi-Deliliers, E. Angelucci, T. Barbui, R. Bassan, A. Rambaldi (Ospedali Riuniti, Bergamo, Italy) 11:15 - 11:30

0424 DIRECT INTRA BONE TRANSPLANT OF UNRELATED CORD BLOOD CELLS IS ASSOCIATED WITH FAST AND COMPLETE HEMATOLOGIC RECOVERY

F. Frassoni, A. Ibatici, A.M. Raiola, F. Gualandi, N. Sessarego, A. Parodi, S. Pozzi, M. Gobbi, M. Corselli, M. Podestà, G. Piaggio, A. Bacigalupo, F. Frassoni (Centro Cellule Staminali, Genoa, Italy) 11:30 - 11:45

0425 THE ROLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN THE TREATMENT OF WALDENSTRÖM’S MACROGLOBULINAEMIA PATIENTS. ANALYSIS OF 201 CASES FROM THE EUROPEAN BONE MARROW TRANSPLANT REGISTRY (EBMT)

C. Kyriakou, C. Kyriakou, C. Canals, G. Taghipour, C. Gisselbrecht, P. Mazza, M. Kazmi,, E. Montserrat, N. Milpied, D. Niederwieser, K. Indrak, A. Neubauer, A. Kolbe, P. Biron, J. Bay, A. Levis, A. Sureda, N. Schmitz (University College London, London, United Kingdom)

SIMULTANEOUS SESSIONS

10:30 - 11:45 hours, Room: Léhar III+IV

MYELODYSPLASTIC SYNDROMES

Chairs: J. Boultwood (University of Oxford, Oxford, United Kingdom) M. Cazzola (University of Pavia Medical School, Pavia, Italy) 10:30 - 10:45

0426 CYTOGENETIC CHARACTERIZATION BY ARRAY COMPARATIVE GENOMIC HYBRIDIZATION AND FLUORESCENCE IN SITU HIBRIDIZATION OF MESENCHYMAL STEM CELLS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROMES

O. López Villar, F. Martín Sánchez-Guijo, J.L. García, E. Villarón, N. López-Holgado, J.A. Pérez Simón, J. San Miguel, M.C. Cañizo (Hospital Universitario de Salamanca, Salamanca, Spain) 10:45 - 11:00

0427 HAS TREATMENT WITH EPO+/- G-CSF AN IMPACT ON PROGRESSION TO AML AND SURVIVAL IN LOW/INT-1-RISK MDS? A COMPARISON BETWEEN FRENCH-EPO PATIENTS AND THE IMRAW DATABASE

S. PARK, S. Grabar, C. Kelaidi, O. Beyne-Rauzy, F. Picard, D. Vassilieff, V. Coiteux, G. Leroux, P. Leppeley, H. Dombret, M.T. Daniel, S. Cheze, B. Mahe, L. Ades, A. Ferrant, C. Ravoet, N. Vey, M. Escoffre-Barbe, L. Aljassem, K. Bourgeois, P. Greenberg, P. Fenaux, F. Dreyfus (Cochin Hospital, Paris, France) 11:00 - 11:15

0428 TREATMENT OF HIGH RISK MDS AND AML POST-MDS WITH AZACYTIDINE (AZA): CURRENT RESULTS OF THE FRENCH ATU PROGRAM

M. Sebert, E. Hernandez, F. Chermat, D. Bordessoule, M.P. Chaury, C. Dartigeas, S. De Botton, F. Dreyfus, L. Legros, L. Mannone, A. Marfaing-Koka, M.P. Noel, S. Park, T. Prebet, A. Stamatoullas, N. Vey, P. Fenaux, C. Fabre (Hôpital Avicenne, Bobigny, France) 11:15 - 11:30

0429 PROGNOSTIC VALUE OF BONE MARROW HISTOLOGY IN MYELODYSPLASTIC SYNDROMES CLASSIFIED ACCORDING TO WHO CRITERIA

M.G. Della Porta, L. Malcovati, E. Boveri, E. Travaglino, C. Pascutto, M. Maffioli, R. Invernizzi, A. Castello, U. Magrini, L. Lazzarino, M. Cazzola (Univeristy of Pavia, Pavia, Italy) 11:30 - 11:45

0430 A ROLE FOR THE ENDOPLASMIC RETICULUM IN THE APOPTOSIS OF ERYTHROID PRECURSORS IN LOW RISK MYELODYSPLASTIC SYNDROMES

E.G. Gyan, E. Frisan, O. Beyne-Rauzy, J.C. Deschemin, C. Randriamampita, A. Dubart-Kupperschmitt, M. Pla-Brunet, C. Garrido, F. Dreyfus, P. Mayeux, C. Lacombe, E. Solary, M. Fontenay (Institut Cochin, Paris, France)

SIMULTANEOUS SESSIONS

10:30 - 11:45 hours, Room: Stolz I

STEM CELL BIOLOGY AND MICROENVIRONMENT

Chairs: C. Eaves (BC Cancer Research Center, Vancouver, Canada) D. Scadden (Harvard Medical School, Boston, USA) 10:30 - 10:45

0431 INVERSE REGULATION OF HEMATOPOIETIC PROGENITOR CELL EGRESS BY MT1-MMP AND RECK

A. Avigdor, Y. Vagima, P. Goichberg, S. Shivtiel, M. Tesio, A. Dar, A. Kalinkovich, I. Petit, O. Perl, E. Rosenthal, I. Resnick, I. Hardan, A. Nagler, T. Lapidot (The Chaim Sheba Medical Center, Tel-hashomer, Israel) 10:45 - 11:00

0432 SNX5, A NOVEL GENE LINKED TO FANCONI ANAEMIA CAUSES HAEMATOPOIETIC FAILURE WHEN KNOCKED DOWN IN ZEBRAFISH

C. Flynn, E.M. Mendenhall, C.M. Verfaillie (Stem Cell Institute Leuven (SCIL), Leuven, Belgium) 11:00 - 11:15

0433 IMPACT OF STOCHASTIC DYNAMICS ON THE ACTIVE HEMATOPOIETIC STEM CELL POOL

D. Dingli, A. Traulsen, J.M. Pacheco (Mayo Clinic, Rochester, USA) 11:15 - 11:30

0434 A PUTATIVE ROLE FOR VEGFR-1 (FLT-1) IN B CELL COMMITMENT AND DIFFERENTIATION

R. Fragoso, C. Igreja, C. Appleton, A. Henriques, N. Clode, Y. Wu, Z. Zhu, S. Dias (Portuguese institute of Oncology, Lisbon, Portugal) 11:30 - 11:45

0435 RXRa DIFFERENTIALLY REGULATES MYELOID SUBLINEAGE DIFFERENTIATION

S. Taschner, C. Kösters, B. Platzer, A. Jörgl, W. Ellmeier, H. Strobl (Medical University Vienna, Vienna, Austria)

SIMULTANEOUS SESSIONS

10:30 - 11:45 hours, Room: Stolz II

BONE MARROW FAILURE

Chairs: N. Borregaard (Rigshospitalet, Copenhagen, Denmark) C. Dufour (G. Gastini Childeren’s Hospital, Genoa, Italy) 10:30 - 10:45

0436 IMPACT OF SOMATIC CELL MOSAICISM IN FANCONI ANEMIA ON DEVELOPMENT OF BONE MARROW FAILURE

J. Tolar, M.L. MacMillan, S.D. Batish, C. Eide, Y. Flit, S.M. Davies, B.R. Blazar, A. Auerbach, J.E. Wagner (University of Minnesota, Minneapolis, USA) 10:45 - 11:00

0437 INCREASED PRODUCTION OF TGF-BETA1 BY BONE MARROW STROMAL CELLS IS ASSOCIATED WITH DOWNREGULATION OF IL-10 AND OVEREXPRESSION OF SOLUBLE FLT-3 LIGAND IN PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA

H. Papadaki, K. Pyrovolaki, I. Mavroudi, M. Spanoudakis, C. Pontikoglou, M. Ximeri, C. Kalpadaki, G. Gvazava, M. Velegraki, G.D. Eliopoulos (University of Crete School of Medicine, Voutes, Heraklion, Greece) 1 1:00 - 11:15

0438 TERC MUTATIONS ANALYSIS IN PATIENTS WITH APLASTIC ANEMIA: RESULTS OF A DHPLC SCREENING AND CLINICAL IMPLICATIONS

S. Pigullo, C. Dufour, G. Caridi, J. Svahn, G. Santamaria, M. Risso, M. Van Lint, D. Longoni, M. Pillon, A.P. Iori, P. Saracco, A. Bacigalupo, C. Di Grazia, M. Lanciotti (G. Gaslini Hospital, Genoa, Italy) 11:15 - 11:30

0439 ADIPONECTIN IS PRODUCED BY LYMPHOCYTES AND INHIBITS GRANULOPOIESIS

L. Crawford, W. Peake, S. Price, T.C.M. Morris, A.E. Irvine (Queen's University Belfast, Belfast, United Kingdom) 11:30 - 11:45

0440 ABSENCE OF LEF-1 TRANSCRIPTION FACTOR IN MYELOID PROGENITORS OF PATIENTS WITH SEVERE CONGENITAL NEUTROPENIA RESULTED IN ABROGATED EXPRESSION OF NEUTROPHIL ELASTASE (NE) AND DEFECTIVE GRANULOPOIESIS

J. Skokowa, J.P. Fobiwe, L. Dan, K. Welte (Medical School Hanover, Hanover, Germany)